Details of the Drug

General Information of Drug (ID: DMXZRW0)

Drug Name
DTI-015
Synonyms
Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Approved [1]
Glioblastoma of brain 2A00.00 Approved [2]
Liver cancer 2C12 Approved [3]
Malignant glioma 2A00.0 Approved [4]
Plasma cell myeloma 2A83.1 Approved [5]
Classic Hodgkin lymphoma N.A. Investigative [5]
⏷ Show the Full List of Indication(s)
Affected Organisms
Humans and other mammals
ATC Code
L01AD01: DTI-015
L01AD: Nitrosoureas
L01A: ALKYLATING AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 214.05
Logarithm of the Partition Coefficient (xlogp) 1.5
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability
The bioavailability of drug is 5-28% []
Clearance
The drug present in the plasma can be removed from the body at the rate of 78 mL/min/kg [7]
Elimination
0.5% of drug is excreted from urine in the unchanged form [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 - 30 minutes [7]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.5498 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.23% [7]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 3.8 mg/mL [6]
Chemical Identifiers
Formula
C5H9Cl2N3O2
IUPAC Name
1,3-bis(2-chloroethyl)-1-nitrosourea
Canonical SMILES
C(CCl)NC(=O)N(CCCl)N=O
InChI
InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
InChIKey
DLGOEMSEDOSKAD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2578
ChEBI ID
CHEBI:3423
CAS Number
154-93-8
UNII
U68WG3173Y
DrugBank ID
DB00262
TTD ID
D01OXI
INTEDE ID
DR0278
ACDINA ID
D00918
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Binder [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Glutathione S-transferase alpha-1 (GSTA1) DE4ZHS1 GSTA1_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
14-3-3 protein eta OTP8NJFJ 1433F_HUMAN Gene/Protein Processing [11]
2-hydroxyacylsphingosine 1-beta-galactosyltransferase OT17ST61 CGT_HUMAN Gene/Protein Processing [11]
3-mercaptopyruvate sulfurtransferase (MPST) OTCDPH5D THTM_HUMAN Drug Response [12]
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2) OTU1KZPV AAPK2_HUMAN Drug Response [12]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) OTG7NW98 F262_HUMAN Gene/Protein Processing [11]
A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) OT4CA13K ATS4_HUMAN Gene/Protein Processing [11]
Acetylcholine receptor subunit gamma (CHRNG) OTXC2UR7 ACHG_HUMAN Gene/Protein Processing [11]
Actin, alpha cardiac muscle 1 (ACTC1) OTJU04B1 ACTC_HUMAN Gene/Protein Processing [11]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Gene/Protein Processing [11]
Actin-binding protein WASF2 OTRT4F55 WASF2_HUMAN Drug Response [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 7.4677 9.5689 4.2117 0.6377
ES7 GDSC2 5.2912 14.0175 0.6678 22.9042
EW-13 GDSC2 5.6321 7.8117 4.0053 3.9121
NY GDSC2 5.7696 9.7359 3.1681 8.6952
EW-11 GDSC2 5.8569 10.0151 3.0947 8.9297
A-673 GDSC2 5.9368 12.6238 1.8695 15.6236
ES5 GDSC2 6.0106 9.3226 3.5374 5.9286
ES4 GDSC2 6.0499 9.3914 3.5308 5.8859
EW-3 GDSC2 6.1069 10.6444 2.9663 9.1133
EW-22 GDSC2 6.1113 10.3584 3.1079 8.2685
ES6 GDSC2 6.1518 8.6142 3.9593 3.2003
ES8 GDSC2 6.3416 8.6288 4.0618 2.3477
CAL-72 GDSC2 6.4442 8.2689 4.2685 1.2156
MHH-ES-1 GDSC2 6.6824 8.8223 4.1562 1.4635
EW-24 GDSC2 6.7219 8.1662 4.4308 0.4044
HuO-3N1 GDSC2 6.7541 9.141 4.059 1.8282
CADO-ES1 GDSC2 6.8256 8.4629 4.3625 0.5488
H-EMC-SS GDSC2 6.905 9.7338 3.8849 2.4809
HuO9 GDSC2 6.9054 9.5302 3.9717 2.0615
EW-1 GDSC2 6.9111 9.7257 3.8916 2.4404
TC-71 GDSC2 6.933 8.4297 4.4176 0.3405
MG-63 GDSC2 7.0528 8.9607 4.2691 0.7067
CAL-78 GDSC2 7.1135 9.2667 4.1774 0.9837
HOS GDSC2 7.1236 8.4458 4.4823 0.1499
U2OS GDSC2 7.148 9.8234 3.9699 1.7996
SaOS-2 GDSC2 7.2396 9.0559 4.3097 0.4793
SK-ES-1 GDSC2 7.2672 8.9379 4.363 0.3349
NOS-1 [Human HNSCC] GDSC2 7.2947 9.5823 4.134 1.0044
CHSA8926 GDSC2 7.2956 9.514 4.1607 0.909
G-292 clone A141B1 GDSC2 7.3361 9.7325 4.0937 1.1205
SK-PN-DW GDSC2 7.3519 9.0887 4.3412 0.3519
EW-18 GDSC2 7.505 9.6714 4.1887 0.6852
EW-7 GDSC2 7.5875 9.2857 4.3592 0.2381
EW-16 GDSC2 7.7246 9.607 4.2972 0.3148
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-220 GDSC2 5.4037 8.3677 3.5711 7.113
ESO-26 GDSC2 5.9475 8.0342 4.1018 2.7486
OACM5.1 C GDSC2 6.1091 8.3773 4.0417 2.8134
KYSE-50 GDSC2 6.8685 8.7497 4.2712 0.828
KYAE-1 GDSC2 7.2465 8.9198 4.3616 0.3461
FLO-1 GDSC2 7.3061 9.719 4.0856 1.1747
ESO-51 GDSC2 7.3281 9.3912 4.2211 0.6892
SK-GT-4 GDSC2 7.465 13.8307 2.3542 9.6794
TE-12 GDSC2 7.6672 17.9809 0.5029 17.7767
OACP4 C GDSC2 7.9794 9.8577 4.3027 0.2326
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 7.2727 9.3 4.2325 0.6867
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB(TU)1 GDSC2 5.0824 6.7074 4.1484 4.316
Kelly GDSC2 5.442 7.9808 3.7899 5.6589
SK-N-DZ GDSC2 5.4631 7.9063 3.8417 5.288
GOTO GDSC2 5.529 15.6893 0.025 24.6697
SJNB-14 GDSC2 5.6484 7.9539 3.9482 4.2219
NB69 GDSC2 5.6933 8.1039 3.9068 4.3772
CHP-212 GDSC2 5.7849 8.3228 3.8636 4.4458
SK-N-BE(2)-M17 GDSC2 5.8029 7.6302 4.1997 2.4452
KP-N-YN GDSC2 5.8132 18.3224 -1.0614 27.3413
IMR-5 GDSC2 5.8628 15.7232 0.2732 22.8874
SK-N-AS GDSC2 6.242 9.5307 3.5904 5.1511
SJNB-13 GDSC2 6.7937 8.6458 4.2788 0.8572
CHP-134 GDSC2 6.8055 8.4439 4.3614 0.5645
SJNB-10 GDSC2 6.8476 8.7766 4.2515 0.9165
GI-ME-N GDSC2 6.9131 9.5669 3.9601 2.1072
SiMa GDSC2 6.9221 9.9649 3.7942 2.9122
TGW GDSC2 6.9526 8.7996 4.2881 0.7093
NH-12 GDSC2 7.0536 9.319 4.1299 1.2155
SJNB-7 GDSC2 7.3422 8.9948 4.3709 0.2905
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 6.3171 9.6648 3.5754 5.0954
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-453 GDSC2 5.1697 7.9778 3.5846 7.6341
CAL-120 GDSC2 5.4612 7.6532 3.9638 4.5393
MDA-MB-468 GDSC2 5.5242 7.6716 3.999 4.1817
HCC1806 GDSC2 5.6433 7.3495 4.2312 2.5514
T-47D GDSC2 5.8064 9.3842 3.3664 7.4075
MDA-MB-361 GDSC2 5.8168 8.008 4.0332 3.3783
BT-20 GDSC2 5.9694 8.3495 3.9699 3.4612
DU4475 GDSC2 5.9701 7.6868 4.2711 1.7899
OCUB-M GDSC2 6.2664 8.2134 4.202 1.7362
HCC1954 GDSC2 6.2814 8.8386 3.934 3.1261
HCC1500 GDSC2 6.2861 8.6277 4.0313 2.5908
HCC1937 GDSC2 6.337 8.3134 4.196 1.6756
Evsa-T GDSC2 6.3917 7.8589 4.4089 0.6885
BT-474 GDSC2 6.4338 8.099 4.3326 0.9521
MFM-223 GDSC2 6.5032 8.1666 4.3375 0.8706
HDQ-P1 GDSC2 6.6055 8.5024 4.2502 1.1336
HCC70 GDSC2 6.6489 8.7712 4.1609 1.478
MCF-7 GDSC2 6.698 8.953 4.1097 1.6571
MRK-nu-1 GDSC2 6.7105 8.1616 4.4279 0.4183
HCC38 GDSC2 6.7242 10.2387 3.5601 4.4591
JIMT-1 GDSC2 6.7589 8.477 4.3291 0.7023
CAL-85-1 GDSC2 6.7774 9.0501 4.1085 1.5754
MDA-MB-157 GDSC2 6.828 8.8594 4.2099 1.0942
HCC1569 GDSC2 6.8414 9.1955 4.0796 1.6361
EFM-192A GDSC2 6.8434 8.3041 4.4283 0.3529
EFM-19 GDSC2 6.8786 10.5763 3.498 4.5444
MDA-MB-330 GDSC2 6.8945 9.0939 4.1466 1.2922
Hs 578T GDSC2 6.895 9.3567 4.0392 1.7606
HCC2157 GDSC2 6.9177 9.153 4.1336 1.3247
CAMA-1 GDSC2 7.0033 8.5096 4.4158 0.3159
HCC1419 GDSC2 7.0591 8.7127 4.364 0.4207
MDA-MB-415 GDSC2 7.1138 9.7255 3.9936 1.7307
AU565 GDSC2 7.1191 9.1075 4.2412 0.7556
HCC1187 GDSC2 7.1657 8.7723 4.3836 0.3268
MDA-MB-436 GDSC2 7.1941 9.1661 4.2504 0.6781
ZR-75-30 GDSC2 7.2523 9.0262 4.3255 0.4318
HCC1428 GDSC2 7.3558 8.7486 4.4609 0.1322
CAL-51 GDSC2 7.4045 9.0057 4.39 0.2337
BT-549 GDSC2 7.4436 9.4735 4.2373 0.5768
MDA-MB-231 GDSC2 7.4966 9.5523 4.2295 0.5718
COLO 824 GDSC2 7.9087 10.0611 4.2053 0.4486
HCC1143 GDSC2 8.0437 10.2105 4.2031 0.4028
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AM-38 GDSC2 5.6995 8.1905 3.8694 4.5894
SW1088 GDSC2 5.8531 8.337 3.9017 4.0809
A-172 GDSC2 5.9145 8.6463 3.7955 4.5877
GaMG GDSC2 6.1239 8.0665 4.189 1.9971
KS-1 [Human Krukenberg tumour] GDSC2 6.178 9.046 3.7764 4.194
D-392MG GDSC2 6.2503 8.2672 4.1701 1.9177
LN-18 GDSC2 6.3443 7.3661 4.5741 0.2074
PFSK-1 GDSC2 6.3987 8.6139 4.0993 2.0756
M059J GDSC2 6.4099 8.6804 4.0765 2.1764
ONS-76 GDSC2 6.4141 8.3288 4.2288 1.4277
SF539 GDSC2 6.4308 8.3766 4.2171 1.463
D-263MG GDSC2 6.5315 9.49 3.7859 3.5343
Becker GDSC2 6.5789 11.2372 3.0032 7.8829
H4 GDSC2 6.6831 16.704 0.4153 20.3125
CAS-1 GDSC2 6.734 8.1722 4.4334 0.3911
U-87MG ATCC GDSC2 6.7703 8.1823 4.444 0.3456
42-MG-BA GDSC2 6.7815 8.672 4.2631 0.9259
GI-1 GDSC2 6.7934 9.0318 4.1238 1.4902
SK-MG-1 GDSC2 6.8054 9.6801 3.8551 2.7624
YH-13 GDSC2 6.8068 8.5737 4.3125 0.7263
LN-405 GDSC2 6.8535 8.4268 4.3873 0.459
D283 Med GDSC2 6.8584 8.6407 4.3088 0.703
8-MG-BA GDSC2 6.8727 11.3029 3.1609 6.4216
DK-MG GDSC2 6.8783 8.1063 4.5114 0.1624
T98G GDSC2 6.9419 12.7642 2.5174 9.8495
GB-1 GDSC2 6.9753 9.0328 4.2078 0.979
DBTRG-05MG GDSC2 7.0068 8.9307 4.2611 0.7642
LN-229 GDSC2 7.0605 8.461 4.4543 0.2144
KINGS-1 GDSC2 7.0921 15.8448 1.1348 16.3801
U-251MG GDSC2 7.1378 8.9269 4.3166 0.5115
Daoy GDSC2 7.3568 8.796 4.4451 0.1543
SF268 GDSC2 7.3785 9.4152 4.2327 0.625
U-118MG GDSC2 7.4656 8.935 4.4361 0.1447
KALS-1 GDSC2 8.0673 9.9514 4.3018 0.2132
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 6.7784 14.501 1.566 15.0973
ETK-1 GDSC2 7.3321 9.1738 4.303 0.4535
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 GDSC2 5.7659 8.5062 3.763 5.0908
AN3-CA GDSC2 6.0318 8.6597 3.8646 3.955
MFE-319 GDSC2 7.1481 8.6687 4.4137 0.2673
KLE GDSC2 7.193 9.1381 4.2604 0.6473
EN GDSC2 7.3422 8.5588 4.5197 0.0679
ESS-1 GDSC2 7.3893 8.8205 4.4482 0.1431
MFE-296 GDSC2 7.4135 9.2287 4.3146 0.3897
MFE-280 GDSC2 8.1486 10.5088 4.1364 0.5146
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 128 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DEL GDSC2 5.103 6.4482 4.2929 3.3531
AMO1 GDSC2 5.1255 9.325 2.8772 12.1363
SR GDSC2 5.1531 7.1626 3.9771 5.2085
OCI-AML-2 GDSC2 5.1703 6.4943 4.3205 3.0135
SU-DHL-10 GDSC2 5.1935 6.6216 4.2751 3.24
P32/ISH GDSC2 5.1986 7.5136 3.8379 5.9657
SCC-3 GDSC2 5.3123 7.0604 4.1464 3.7564
P12-Ichikawa GDSC2 5.3519 7.4543 3.9823 4.6799
Karpas-231 GDSC2 5.3679 6.9884 4.2208 3.1727
LC4-1 GDSC2 5.3786 7.8529 3.8061 5.711
ML-2 GDSC2 5.425 7.3192 4.1004 3.7819
ST486 GDSC2 5.4874 7.801 3.9105 4.8074
OCI-M1 GDSC2 5.4979 7.2651 4.1765 3.1619
RS4;11 GDSC2 5.5307 8.5917 3.555 6.9006
H9 GDSC2 5.5393 7.5968 4.0455 3.8662
GA-10 GDSC2 5.5443 7.861 3.9214 4.6114
RPMI-8226 GDSC2 5.6105 8.2819 3.7637 5.4283
JURL-MK1 GDSC2 5.619 7.9826 3.9144 4.4897
U-698-M GDSC2 5.623 7.5042 4.1455 3.0927
Karpas-422 GDSC2 5.6246 7.396 4.1976 2.7825
U266B1 GDSC2 5.6325 7.5952 4.1087 3.2923
JVM-3 GDSC2 5.6746 7.6119 4.1281 3.0944
MHH-CALL-2 GDSC2 5.6754 7.3227 4.2635 2.3065
L-540 GDSC2 5.6774 7.4026 4.2278 2.5079
BC-1 GDSC2 5.6883 8.9268 3.5051 6.835
697 GDSC2 5.6886 7.7626 4.0661 3.4334
IM-9 GDSC2 5.7173 9.2033 3.3909 7.4654
EoL-1 GDSC2 5.7297 7.4726 4.2277 2.4148
HAL-01 GDSC2 5.7373 8.7347 3.6331 5.942
MHH-PREB-1 GDSC2 5.7383 7.4256 4.2545 2.2479
MOLM-13 GDSC2 5.7473 8.682 3.6655 5.7223
KM-H2 GDSC2 5.7515 8.225 3.8879 4.369
ME1 GDSC2 5.764 7.3248 4.3155 1.866
ALL-SIL GDSC2 5.7967 7.4571 4.2749 2.0363
Reh GDSC2 5.7976 7.5275 4.2434 2.2091
SUP-M2 GDSC2 5.8158 8.4945 3.8023 4.7491
PF-382 GDSC2 5.8378 8.5694 3.7813 4.8292
LAMA-84 GDSC2 5.8411 9.5441 3.3132 7.6503
SKM-1 GDSC2 5.8445 7.0649 4.4728 0.9455
DND-41 GDSC2 5.8694 8.051 4.0462 3.2041
OCI-AML-5 GDSC2 5.8796 8.5344 3.8256 4.4791
Karpas-45 GDSC2 5.8869 8.1927 3.9912 3.4908
SUP-HD1 GDSC2 5.9882 8.1366 4.0794 2.805
CML-T1 GDSC2 6.0172 9.1705 3.6143 5.4567
CCRF-CEM GDSC2 6.03 7.6803 4.3065 1.5246
SUP-T1 GDSC2 6.0431 8.1707 4.0964 2.6188
Jiyoye GDSC2 6.0527 8.6172 3.8974 3.7265
L-1236 GDSC2 6.0661 9.4657 3.5061 5.9991
Loucy GDSC2 6.0782 7.9014 4.2363 1.8165
BE-13 GDSC2 6.0866 10.2312 3.1523 8.0605
EB2 GDSC2 6.089 7.8734 4.2544 1.7087
HEL GDSC2 6.1272 13.203 1.7267 15.8665
MOLT-13 GDSC2 6.136 8.6394 3.9383 3.3458
RPMI-8866 GDSC2 6.1473 8.2261 4.1315 2.2658
GR-ST GDSC2 6.1506 8.7922 3.8769 3.668
Hs 445 GDSC2 6.1824 8.0362 4.2339 1.6869
WSU-NHL GDSC2 6.1939 10.6592 3.0199 8.6038
SU-DHL-5 GDSC2 6.1995 7.2413 4.563 0.3018
NCI-H929 GDSC2 6.2108 11.8854 2.4356 11.9109
MLMA GDSC2 6.2156 8.1896 4.1852 1.8883
A3/Kawakami GDSC2 6.2228 7.3282 4.5401 0.3563
JSC-1 GDSC2 6.2549 8.4435 4.0955 2.297
Ku812 GDSC2 6.2665 8.3736 4.1325 2.0877
DB GDSC2 6.2953 8.0472 4.2873 1.2922
MM1.S GDSC2 6.3433 7.765 4.4242 0.6695
ARH-77 GDSC2 6.3594 8.3019 4.2125 1.5685
P30/OHK GDSC2 6.3782 8.2149 4.2585 1.3317
Kasumi-1 GDSC2 6.3886 9.1237 3.8678 3.3158
KG-1 GDSC2 6.4226 8.036 4.3528 0.8804
SU-DHL-6 GDSC2 6.5059 8.3446 4.2671 1.1587
GDM-1 GDSC2 6.524 8.5636 4.1855 1.5035
TK [Human B-cell lymphoma] GDSC2 6.5413 8.0136 4.4138 0.5624
DoHH2 GDSC2 6.5705 8.2946 4.3173 0.8925
Karpas-1106P GDSC2 6.6 8.1802 4.375 0.6548
Raji GDSC2 6.6287 8.1186 4.4106 0.517
MOLT-16 GDSC2 6.6832 8.9836 4.0894 1.7682
Ramos.2G6.4C10 GDSC2 6.6942 8.0034 4.4792 0.2906
VAL GDSC2 6.719 8.8911 4.1456 1.4718
TUR GDSC2 6.7237 8.439 4.3286 0.7292
Farage GDSC2 6.7256 8.333 4.37 0.5869
JJN-3 GDSC2 6.7651 8.4078 4.3582 0.6003
K-562 GDSC2 6.7658 8.3878 4.3661 0.5742
EM-2 GDSC2 6.7846 8.5205 4.3234 0.704
A4/Fukuda GDSC2 6.7894 8.1368 4.4678 0.2793
MOLP-8 GDSC2 6.7996 8.5054 4.3356 0.6522
BALL-1 GDSC2 6.8267 8.4184 4.3796 0.4962
SU-DHL-8 GDSC2 6.8585 8.1093 4.5032 0.1824
KOPN-8 GDSC2 6.8624 8.8419 4.2325 0.9768
KE-37 GDSC2 6.8676 8.1208 4.5025 0.1811
RPMI-6666 GDSC2 6.8776 8.925 4.2064 1.0652
MOLT-4 GDSC2 6.892 8.3989 4.4128 0.3705
KMS-12-BM GDSC2 6.8928 8.5782 4.3469 0.5574
BL-41 GDSC2 6.898 8.1212 4.5133 0.1541
SUP-B15 GDSC2 6.9071 8.3807 4.4253 0.3326
Karpas-299 GDSC2 6.9114 9.6823 3.9103 2.3487
OPM-2 GDSC2 6.9427 8.4421 4.4168 0.3382
LP-1 GDSC2 6.9508 8.4845 4.4046 0.3651
KCL-22 GDSC2 6.957 8.7179 4.3209 0.5999
Namalwa GDSC2 6.9717 8.8726 4.2683 0.7636
HL-60 GDSC2 6.983 8.0555 4.5651 0.0692
Daudi GDSC2 6.9895 8.4484 4.4324 0.2833
ATN-1 GDSC2 6.9934 8.5376 4.4019 0.3532
HC-1 GDSC2 7.007 8.738 4.3339 0.5315
SK-MM-2 GDSC2 7.0304 8.7952 4.3221 0.5536
NALM-6 GDSC2 7.0321 9.5438 4.0288 1.6607
CESS GDSC2 7.0446 8.939 4.2739 0.6962
Jurkat GDSC2 7.0467 8.5143 4.4305 0.2668
OCI-AML-3 GDSC2 7.0485 8.5323 4.4248 0.2785
Karpas-620 GDSC2 7.0492 8.3063 4.5036 0.1342
RC-K8 GDSC2 7.0671 8.4481 4.4612 0.1997
WIL2 NS GDSC2 7.0687 8.6618 4.3862 0.3599
Granta-519 GDSC2 7.074 8.7308 4.3632 0.4157
NOMO-1 GDSC2 7.0924 8.5436 4.4371 0.238
HH [Human lymphoma] GDSC2 7.1151 10.9745 3.4558 4.3953
CTV-1 GDSC2 7.1178 9.3219 4.1577 1.0538
L-363 GDSC2 7.1435 8.7536 4.3819 0.3395
JVM-2 GDSC2 7.1487 9.1558 4.2353 0.7556
CA46 GDSC2 7.1668 8.8674 4.3498 0.4081
L-428 GDSC2 7.1678 8.8528 4.3555 0.3933
KY821 GDSC2 7.2722 9.1239 4.2977 0.496
DG-75 GDSC2 7.2976 9.2799 4.2502 0.618
ALL-PO GDSC2 7.3657 9.9597 4.0172 1.3909
VL51 GDSC2 7.4398 9.4223 4.2546 0.5308
EJM GDSC2 7.5789 8.9984 4.4539 0.1029
KMOE-2 GDSC2 7.6203 9.343 4.3512 0.2433
HDLM-2 GDSC2 7.6456 9.5462 4.2893 0.3585
MN-60 GDSC2 7.7479 9.6219 4.3006 0.3007
MEG-01 GDSC2 7.8356 9.9432 4.2196 0.444
⏷ Show the Full List of 128 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB996-RCC GDSC2 5.3122 7.6243 3.8694 5.4798
RCC10RGB GDSC2 5.4224 7.3638 4.077 3.9313
SW13 GDSC2 5.523 8.1285 3.7762 5.5527
769-P GDSC2 5.627 8.7996 3.5232 6.867
786-O GDSC2 5.9846 10.4661 2.9662 9.3951
KTCTL-195 GDSC2 6.093 8.1817 4.1204 2.408
SN12C GDSC2 6.119 8.658 3.9194 3.4818
CAL-54 GDSC2 6.4462 10.7413 3.1513 7.3015
TK-10 GDSC2 6.4727 9.3748 3.8036 3.5321
A-498 GDSC2 6.6251 8.0236 4.4447 0.4157
HA7-RCC GDSC2 6.6334 9.0141 4.051 2.0112
ACHN GDSC2 6.7548 9.1149 4.0703 1.7746
A-704 GDSC2 6.8205 8.6217 4.2999 0.7608
BFTC-909 GDSC2 6.9117 9.1331 4.1388 1.3083
RXF 393L GDSC2 7.1053 10.014 3.8692 2.3095
VMRC-RCZ GDSC2 7.1397 9.0208 4.2825 0.6108
OS-RC-2 GDSC2 7.2352 8.675 4.4434 0.1856
KMRC-20 GDSC2 7.3335 8.7516 4.452 0.1491
NCC010 GDSC2 8.0254 10.2372 4.1867 0.446
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-CO-1 GDSC2 4.4611 6.1859 3.8663 8.0099
SW1116 GDSC2 5.3143 8.5921 3.3918 8.4574
T84 GDSC2 5.3618 7.5042 3.9651 4.7631
RCM-1 [Human ESC] GDSC2 5.7102 7.5417 4.1836 2.703
CCK-81 GDSC2 5.7407 11.5408 2.2566 14.0674
HCT 116 GDSC2 5.8311 7.3922 4.3237 1.7172
HCT 15 GDSC2 5.8365 8.0753 4.0142 3.4515
HT-29 GDSC2 6.0408 7.9997 4.172 2.2107
SW48 GDSC2 6.0682 9.9228 3.2884 7.2918
LoVo GDSC2 6.1706 8.9125 3.8337 3.8788
SW837 GDSC2 6.1722 8.9176 3.8323 3.8838
HCC2998 GDSC2 6.1956 9.9115 3.3799 6.4785
C2BBe1 GDSC2 6.235 12.3931 2.2047 13.1173
CL-11 GDSC2 6.2576 9.4685 3.6295 4.8944
SW620 GDSC2 6.3582 8.2496 4.2339 1.4684
RKO GDSC2 6.3605 8.1894 4.2604 1.3426
SW1463 GDSC2 6.3651 9.599 3.6361 4.6572
GP5d GDSC2 6.4228 8.0605 4.343 0.9197
KM12 GDSC2 6.4235 8.946 3.9673 2.7248
LS411N GDSC2 6.474 7.6811 4.5105 0.3093
HT115 GDSC2 6.5958 8.3519 4.306 0.9152
CW-2 GDSC2 6.6223 8.9036 4.0923 1.8263
SNU-81 GDSC2 6.6454 8.7416 4.1715 1.4345
SNU-61 GDSC2 6.659 8.4494 4.296 0.9007
SNU-175 GDSC2 6.7086 8.7667 4.1916 1.2815
SNU-407 GDSC2 6.7172 10.6122 3.3846 5.4487
SW948 GDSC2 6.7356 8.2807 4.3938 0.5053
SNU-C1 GDSC2 6.7544 10.2363 3.579 4.3047
LS123 GDSC2 6.7625 8.5181 4.3148 0.7499
MDST8 GDSC2 6.7663 8.1506 4.4539 0.3221
COLO205 GDSC2 6.8072 8.3115 4.4113 0.4152
CaR-1 GDSC2 6.8072 9.0899 4.1066 1.552
SNU-1040 GDSC2 6.8615 8.1713 4.4826 0.2212
COLO 320HSR GDSC2 6.8752 8.667 4.3059 0.7014
HT-55 GDSC2 6.9086 8.2394 4.4761 0.2191
SNU-C5 GDSC2 6.9647 8.8952 4.2566 0.8092
SW626 GDSC2 6.9734 10.418 3.6234 3.7232
SNU-C2B GDSC2 7.0181 10.2874 3.7056 3.2314
LS513 GDSC2 7.0316 8.5509 4.4118 0.3139
DiFi GDSC2 7.1276 9.5056 4.0893 1.3127
LS180 GDSC2 7.1418 11.4246 3.2685 5.3592
LS1034 GDSC2 7.2596 9.3783 4.1974 0.8087
NCI-H716 GDSC2 7.398 9.6889 4.1375 0.9178
COLO 678 GDSC2 7.4067 9.4905 4.2162 0.6586
NCI-H747 GDSC2 7.5686 9.601 4.2401 0.5081
SW1417 GDSC2 7.8172 9.5283 4.3579 0.184
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 7.1698 8.8142 4.3702 0.3565
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-423 GDSC2 5.168 7.4903 3.8258 6.1216
SNU-398 GDSC2 5.6279 7.5513 4.1265 3.196
JHH-7 GDSC2 5.833 9.6739 3.2442 8.0862
JHH-6 GDSC2 5.8675 6.7994 4.5914 0.4205
SNU-387 GDSC2 5.9978 8.4297 3.9503 3.522
SK-HEP-1 GDSC2 6.0278 8.7392 3.8249 4.1934
HLE GDSC2 6.268 9.9332 3.4174 6.111
Hep 3B2.1-7 GDSC2 6.3472 8.2983 4.2078 1.6062
JHH-1 GDSC2 6.4533 7.904 4.4183 0.608
JHH-4 GDSC2 6.7098 11.3772 3.0226 7.5106
HuH-1 GDSC2 6.743 8.183 4.433 0.3876
Hep-G2/C3A GDSC2 6.8498 8.1326 4.4918 0.2065
SNU-449 GDSC2 7.37 9.2721 4.282 0.4908
Huh-7 GDSC2 7.3793 9.1067 4.3452 0.3328
JHH-2 GDSC2 7.6124 9.5408 4.2787 0.3947
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 129 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H209 GDSC2 5.147 8.5075 3.3026 9.4615
EKVX GDSC2 5.3999 8.53 3.488 7.6391
EMC-BAC-2 GDSC2 5.4384 10.0584 2.7596 11.984
NCI-H1155 GDSC2 5.4405 7.2127 4.1627 3.3678
Lu-165 GDSC2 5.4737 7.3227 4.1325 3.4796
NCI-H2141 GDSC2 5.5093 7.6571 3.9957 4.2351
COR-L105 GDSC2 5.5374 9.0597 3.3297 8.2744
IA-LM GDSC2 5.5695 7.5979 4.0655 3.6807
NCI-H810 GDSC2 5.5697 7.3433 4.1869 2.9536
DMS 273 GDSC2 5.5857 7.5221 4.1125 3.3646
NCI-H441 GDSC2 5.5885 13.842 0.9939 20.7108
COR-L23 GDSC2 5.6977 7.3635 4.2584 2.2963
HOP-92 GDSC2 5.7081 9.0149 3.4763 6.9654
NCI-H226 GDSC2 5.7701 7.8077 4.0972 3.0929
NCI-H2085 GDSC2 5.7794 8.4679 3.7906 4.8959
NCI-H3122 GDSC2 5.8187 8.3516 3.8723 4.3249
NCI-H1944 GDSC2 5.8581 7.9679 4.0778 3.0429
NCI-H2810 GDSC2 5.891 9.0777 3.5737 5.9645
NCI-H1355 GDSC2 5.9055 8.1998 3.9996 3.4072
NCI-H1876 GDSC2 5.9103 8.91 3.6672 5.3623
HCC15 GDSC2 5.9237 9.1042 3.5832 5.8378
COLO 668 GDSC2 5.9577 8.2329 4.0166 3.2141
NCI-H1666 GDSC2 5.981 9.5279 3.4187 6.7019
NCI-H520 GDSC2 5.9817 8.1516 4.0687 2.8762
SBC-3 GDSC2 6.0692 8.3441 4.0332 2.9269
NCI-H196 GDSC2 6.1623 8.3851 4.0691 2.5781
LCLC-103H GDSC2 6.1883 7.5044 4.4575 0.6689
SBC-5 GDSC2 6.1914 7.4741 4.4708 0.6154
NCI-H727 GDSC2 6.1997 8.5437 4.0194 2.7891
NCI-H345 GDSC2 6.2126 7.234 4.5709 0.273
NCI-H3255 GDSC2 6.2188 8.8752 3.8802 3.53
NCI-H2122 GDSC2 6.2275 12.2743 2.2574 12.8502
NCI-H358 GDSC2 6.2409 8.8518 3.9041 3.3587
LK-2 GDSC2 6.2469 9.049 3.8175 3.8356
Lu-135 GDSC2 6.2756 8.2086 4.2088 1.6904
Calu-6 GDSC2 6.3007 8.178 4.2349 1.5322
NCI-H1581 GDSC2 6.3037 8.1217 4.2602 1.4085
Ms-1 GDSC2 6.3349 8.1234 4.2751 1.3037
NCI-H1651 GDSC2 6.3688 8.9807 3.9207 3.0587
NCI-H2023 GDSC2 6.3713 8.3362 4.2041 1.5945
DMS 53 GDSC2 6.3989 9.9454 3.496 5.3992
SHP-77 GDSC2 6.4074 7.8231 4.4297 0.6009
HCC78 GDSC2 6.4096 8.4935 4.1569 1.7751
KNS-62 GDSC2 6.4148 8.1515 4.3024 1.0976
NCI-H1869 GDSC2 6.4205 8.9078 3.9826 2.6485
NCI-H513 GDSC2 6.4269 8.5277 4.1513 1.7807
Lu-139 GDSC2 6.4352 8.4649 4.1823 1.6218
NCI-H526 GDSC2 6.4579 8.1501 4.3233 0.9681
NCI-H1623 GDSC2 6.4824 8.8813 4.0282 2.323
UMC-11 GDSC2 6.4855 8.1451 4.338 0.884
NCI-H2461 GDSC2 6.4945 9.6983 3.6694 4.2401
NCI-H2731 GDSC2 6.5351 8.8433 4.0728 2.0291
Calu-3 GDSC2 6.5564 17.6837 -0.1643 22.7342
NCI-H2170 GDSC2 6.5633 8.3733 4.2825 1.0386
EPLC-272H GDSC2 6.5662 9.5994 3.7567 3.6381
HOP-62 GDSC2 6.5746 8.6406 4.1786 1.4791
NCI-H1694 GDSC2 6.5813 8.2543 4.338 0.8037
NCI-H2722 GDSC2 6.5988 8.4211 4.2798 1.0172
LCLC-97TM1 GDSC2 6.6027 9.2572 3.9295 2.6627
DMS 114 GDSC2 6.6096 9.1398 3.9844 2.3726
NCI-H720 GDSC2 6.6286 8.0423 4.4392 0.4298
NCI-H1975 GDSC2 6.6731 8.6321 4.2294 1.1561
CPC-N GDSC2 6.7081 8.4307 4.325 0.7535
NCI-H82 GDSC2 6.7219 8.0495 4.4733 0.2935
LXF 289 GDSC2 6.7245 11.0722 3.1754 6.6167
VMRC-LCD GDSC2 6.7295 8.3577 4.3622 0.6099
NCI-H1993 GDSC2 6.7572 9.2586 4.0109 2.0524
NCI-H2228 GDSC2 6.7714 9.7415 3.8096 3.0439
NCI-H1781 GDSC2 6.7786 12.6202 2.4765 10.4125
PC-14 GDSC2 6.7844 8.7607 4.2293 1.0552
NCI-H250 GDSC2 6.8047 8.7803 4.2308 1.0318
HARA [Human squamous cell lung carcinoma] GDSC2 6.8075 11.2124 3.1623 6.5345
NCI-H446 GDSC2 6.8178 8.5323 4.333 0.6488
Lu-65 GDSC2 6.8366 8.635 4.3017 0.7428
NCI-H1915 GDSC2 6.8457 8.5201 4.3493 0.5781
NCI-H2803 GDSC2 6.8893 8.6329 4.3249 0.6292
NCI-H661 GDSC2 6.902 8.751 4.2852 0.7541
NCI-H1299 GDSC2 6.9029 8.78 4.2744 0.791
NCI-H2087 GDSC2 6.9167 9.0492 4.1748 1.1566
NCI-H2869 GDSC2 6.9205 9.2756 4.085 1.5293
LC-1/sq GDSC2 6.9624 9.8919 3.8472 2.5933
NCI-H524 GDSC2 7.031 8.6482 4.3764 0.4012
NCI-H23 GDSC2 7.0515 8.7432 4.3498 0.4626
NCI-H841 GDSC2 7.0726 8.8099 4.3337 0.4969
NCI-H2227 GDSC2 7.0939 8.8921 4.3118 0.5488
NCI-H2795 GDSC2 7.1117 9.916 3.9136 2.0943
NCI-H2373 GDSC2 7.1449 9.3529 4.1576 1.0327
NCI-H1563 GDSC2 7.1519 8.8087 4.3652 0.376
NCI-H2405 GDSC2 7.1596 9.1926 4.2258 0.78
HCC44 GDSC2 7.162 9.3536 4.1649 0.9925
RERF-LC-Sq1 GDSC2 7.1767 9.8863 3.9579 1.8225
NCI-H1755 GDSC2 7.235 9.3748 4.1883 0.8563
NCI-H1092 GDSC2 7.2383 9.0328 4.3176 0.4589
NCI-H1568 GDSC2 7.2416 12.2346 2.9577 6.8756
DMS 79 GDSC2 7.2422 8.788 4.4066 0.2508
Lu-99A GDSC2 7.2436 9.4177 4.1755 0.8945
NCI-H1435 GDSC2 7.247 9.0044 4.3314 0.4192
EBC-1 GDSC2 7.2479 9.423 4.1753 0.8922
COR-L311 GDSC2 7.2486 9.144 4.2809 0.5551
NCI-H2029 GDSC2 7.252 8.882 4.3771 0.309
RERF-LC-KJ GDSC2 7.28 8.8654 4.3934 0.2652
SW1573 GDSC2 7.2812 10.3086 3.834 2.2692
NCI-H596 GDSC2 7.3183 9.0499 4.3423 0.3625
SK-LU-1 GDSC2 7.329 9.1636 4.3055 0.4484
NCI-H2135 GDSC2 7.3307 8.9046 4.3983 0.2398
NCI-H2818 GDSC2 7.3307 9.2404 4.2781 0.5206
NCI-H2369 GDSC2 7.3371 8.7834 4.4425 0.1626
NCI-H650 GDSC2 7.3731 9.5575 4.177 0.8018
IST-SL2 GDSC2 7.4009 9.5066 4.2078 0.6873
NCI-H2804 GDSC2 7.4115 9.8241 4.0911 1.0718
NCI-H2595 GDSC2 7.4239 9.1389 4.3505 0.3055
NCI-H211 GDSC2 7.4245 8.9701 4.4096 0.1943
NCI-H522 GDSC2 7.436 9.2531 4.3145 0.381
HCC827 GDSC2 7.4464 9.3519 4.2829 0.4535
LOU-NH91 GDSC2 7.4467 9.2211 4.3299 0.3417
NCI-H1792 GDSC2 7.4482 9.3124 4.2978 0.4156
SW1271 GDSC2 7.4494 9.466 4.2424 0.5596
A-427 GDSC2 7.4629 10.0523 4.0245 1.2796
NCI-H1793 GDSC2 7.4787 9.3576 4.2933 0.4139
HCC366 GDSC2 7.4794 9.3565 4.294 0.412
NCI-H1693 GDSC2 7.546 9.0758 4.4165 0.156
NCI-H1650 GDSC2 7.571 9.3404 4.3341 0.2903
ABC-1 GDSC2 7.6416 9.8358 4.1829 0.6279
NCI-H1048 GDSC2 7.664 9.3397 4.3681 0.2033
SK-MES-1 GDSC2 7.6915 9.4719 4.3323 0.2575
NCI-H1963 GDSC2 7.7919 9.8474 4.2373 0.4202
NCI-H2591 GDSC2 8.0476 10.1182 4.237 0.3316
NCI-H322M GDSC2 8.1775 10.6767 4.0869 0.6261
A-549 GDSC2 8.318 16.7625 1.5236 12.1271
⏷ Show the Full List of 129 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 7.0723 9.1237 4.2149 0.8788
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-180 GDSC2 5.4053 10.1923 2.6673 12.6171
TE-1 GDSC2 6.0459 7.8373 4.2467 1.8079
COLO 680N GDSC2 6.2116 9.5711 3.5518 5.4356
TE-5 GDSC2 6.2196 8.1232 4.2161 1.7271
KYSE-410 GDSC2 6.3787 8.6118 4.0895 2.1527
TE-8 GDSC2 6.5655 9.136 3.9622 2.5461
TE-6 GDSC2 6.5911 8.5968 4.2047 1.3439
KYSE-510 GDSC2 6.694 14.5513 1.4808 15.6983
OE19 GDSC2 6.7017 8.2345 4.3972 0.5149
KYSE-450 GDSC2 6.7472 10.374 3.5121 4.6853
KYSE-70 GDSC2 6.8702 9.7331 3.8668 2.616
TE-9 GDSC2 6.8922 8.3197 4.4415 0.2999
KYSE-140 GDSC2 6.9839 9.0912 4.1886 1.0449
EC-GI-10 GDSC2 7.0594 8.7682 4.3438 0.4754
TE-4 GDSC2 7.1402 8.8645 4.3405 0.4446
KYSE-520 GDSC2 7.1556 13.2393 2.4327 9.8712
KYSE-270 GDSC2 7.1747 9.3225 4.1824 0.9195
OE21 GDSC2 7.1764 8.7107 4.4095 0.2666
TE-15 GDSC2 7.2581 9.587 4.1161 1.0983
OE33 GDSC2 7.6406 9.9934 4.1238 0.8055
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TOV-112D GDSC2 5.3103 7.5263 3.9163 5.1918
TOV-21G GDSC2 5.3371 7.0726 4.1582 3.6262
A2780 GDSC2 5.4912 7.5264 4.0463 3.9658
IGROV-1 GDSC2 5.5771 8.0035 3.8753 4.8203
TYK-nu GDSC2 5.6024 7.5757 4.0981 3.4168
OVISE GDSC2 5.6327 7.1844 4.3011 2.1678
OVK18 GDSC2 5.7534 8.0026 3.9949 3.7264
EFO-27 GDSC2 5.9725 9.5059 3.4235 6.6921
ES-2 GDSC2 6.0331 8.2765 4.0424 2.9363
OV-90 GDSC2 6.5551 8.6127 4.1805 1.4918
OVTOKO GDSC2 6.6141 9.2492 3.9392 2.5965
DOV13 GDSC2 6.6955 8.2962 4.3713 0.6021
OAW42 GDSC2 6.7291 7.7818 4.5695 0.106
OV56 GDSC2 6.7376 7.6562 4.6145 0.0523
OVCAR-8 GDSC2 6.7413 9.3962 3.9438 2.4016
EFO-21 GDSC2 6.8397 8.3185 4.4216 0.3717
OVCAR-5 GDSC2 6.8735 8.9086 4.2111 1.0502
OVCAR-3 GDSC2 6.9276 8.5783 4.3611 0.4953
Kuramochi GDSC2 7.0342 9.349 4.1089 1.3178
OVCAR-4 GDSC2 7.1301 9.6455 4.0341 1.5393
OAW28 GDSC2 7.2604 9.5605 4.1274 1.0543
SK-OV-3 GDSC2 7.3857 8.9513 4.4021 0.2172
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HPAC GDSC2 5.5864 7.8436 3.959 4.2894
QGP-1 GDSC2 5.8544 8.0413 4.0414 3.2598
HuP-T4 GDSC2 5.9102 8.7558 3.7407 4.9227
Capan-2 GDSC2 5.9645 8.1119 4.0765 2.8619
PaTu 8988t GDSC2 5.9906 8.776 3.7838 4.5063
PL4 GDSC2 5.9927 7.8688 4.203 2.1177
SUIT-2 GDSC2 6.0989 7.9266 4.2366 1.7861
Panc 10.05 GDSC2 6.199 8.7291 3.9351 3.2561
DAN-G GDSC2 6.2036 7.8979 4.3038 1.3203
Capan-1 GDSC2 6.2593 7.96 4.3057 1.2476
KP-2 GDSC2 6.3109 8.9006 3.9232 3.1373
MIA PaCa-2 GDSC2 6.4983 8.0717 4.3727 0.7393
SU.86.86 GDSC2 6.5642 8.422 4.2632 1.1182
CFPAC-1 GDSC2 6.6179 9.9773 3.6159 4.3285
HuP-T3 GDSC2 6.7068 8.4317 4.3241 0.758
KP-4 GDSC2 6.8725 8.6648 4.3056 0.7043
Panc 08.13 GDSC2 6.9015 8.6956 4.3061 0.6831
PaTu 8902 GDSC2 6.9322 8.2386 4.485 0.1947
YAPC GDSC2 6.9501 13.7814 2.0354 12.38
BxPC-3 GDSC2 6.9871 8.8751 4.2739 0.7339
KP-1N GDSC2 7.2028 9.4031 4.1634 0.9669
PSN1 GDSC2 7.4065 8.9698 4.4032 0.2097
KP-3 GDSC2 7.5229 10.5554 3.8503 1.937
Panc 02.03 GDSC2 7.6271 18.0127 0.4593 18.032
HPAF-II GDSC2 7.6711 9.5654 4.292 0.3436
AsPC-1 GDSC2 8.0378 9.917 4.3031 0.2179
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2 5.7637 8.5079 3.7607 5.1095
IST-Mes1 GDSC2 6.3435 9.3108 3.7558 4.0153
NCI-H28 GDSC2 6.4635 8.3958 4.2255 1.3879
NCI-H2052 GDSC2 7.0889 8.8045 4.3422 0.465
MPP 89 GDSC2 7.1869 8.8426 4.3665 0.3583
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 6.0223 10.789 2.8356 10.0738
22Rv1 GDSC2 6.4062 9.3359 3.782 3.7613
PC-3 GDSC2 6.7068 9.1982 4.0105 2.1167
VCaP GDSC2 6.8685 8.2927 4.4421 0.3079
DU145 GDSC2 7.7422 9.4663 4.3525 0.2095
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 6.292 9.0203 3.8578 3.531
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH-4 GDSC2 5.301 7.2623 4.0394 4.4475
GAK GDSC2 5.3811 7.0235 4.2129 3.1915
G-mel GDSC2 5.4136 7.4413 4.0331 4.2213
RPMI-7951 GDSC2 5.5989 9.5522 3.1327 9.3263
A101D GDSC2 5.699 7.9863 3.9668 4.0046
WT2-iPS GDSC2 5.8248 10.4184 2.8736 10.3233
LOX-IMVI GDSC2 6.0172 7.8987 4.2036 2.0771
IGR-1 GDSC2 6.0672 8.0689 4.1561 2.2556
Mel JuSo GDSC2 6.0975 8.5483 3.9568 3.308
HMV-II GDSC2 6.1198 9.2401 3.6485 5.0484
WM278 GDSC2 6.1217 8.4495 4.0164 2.9326
COLO 679 GDSC2 6.1368 8.4883 4.0077 2.9558
WM35 GDSC2 6.153 8.4961 4.0137 2.896
SK-MEL-2 GDSC2 6.1726 7.3322 4.5177 0.4605
A-375 GDSC2 6.2092 8.665 3.9702 3.044
SK-MEL-24 GDSC2 6.2294 12.9784 1.9133 14.6668
M14 GDSC2 6.2506 8.158 4.2174 1.68
WM1552C GDSC2 6.3147 8.4106 4.1425 1.9704
COLO 829 GDSC2 6.4182 8.4574 4.1768 1.6685
IGR-37 GDSC2 6.5007 8.0015 4.4011 0.6344
CP66-MEL GDSC2 6.5074 8.0192 4.3972 0.6435
A2058 GDSC2 6.595 7.845 4.4981 0.2863
SK-MEL-5 GDSC2 6.6213 8.1505 4.3955 0.5707
WM115 GDSC2 6.6421 7.9891 4.4641 0.3527
G-361 GDSC2 6.8546 8.5241 4.3515 0.566
HT-144 GDSC2 6.892 15.8008 1.0127 17.3685
UACC-62 GDSC2 6.9409 8.0243 4.5612 0.0793
UACC-257 GDSC2 6.9696 8.1671 4.523 0.1228
COLO 792 GDSC2 7.211 15.0508 1.6031 13.9606
WM793 GDSC2 7.2704 8.6897 4.4509 0.1649
CHL-1 GDSC2 7.5223 9.2748 4.3391 0.2959
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 5.0036 6.6122 4.1335 4.6227
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYM-1 GDSC2 5.367 8.0069 3.7216 6.2664
SW684 GDSC2 5.6633 7.8263 4.0193 3.7636
MES-SA GDSC2 5.6639 7.3017 4.2662 2.3121
Rh41 GDSC2 5.9011 8.2046 3.9946 3.4444
SW982 GDSC2 5.9076 8.2041 3.9989 3.4072
EW-8 GDSC2 5.9978 9.3255 3.5273 6.0158
SW872 GDSC2 6.2158 11.1396 2.8025 9.8193
Rh30 GDSC2 6.3611 8.0323 4.3255 1.052
G-401 GDSC2 6.3876 9.9217 3.4999 5.3981
RKN GDSC2 6.6472 7.7881 4.5379 0.1794
RD GDSC2 6.6737 9.3434 3.9305 2.5591
SK-UT-1 GDSC2 6.6853 9.8609 3.7081 3.7128
A-204 GDSC2 6.7844 9.4603 3.939 2.3693
HT-1080 GDSC2 7.0211 8.7942 4.3187 0.5691
VA-ES-BJ GDSC2 7.0648 8.5172 4.4362 0.2488
G-402 GDSC2 7.1965 9.618 4.0761 1.3048
GCT GDSC2 7.2963 8.9195 4.3804 0.2864
SK-LMS-1 GDSC2 7.8117 9.3965 4.4005 0.1279
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RF-48 GDSC2 5.602 7.607 4.0829 3.5082
23132/87 GDSC2 5.8073 7.818 4.1158 2.9166
AGS GDSC2 5.8651 11.7851 2.2301 13.8932
NCI-N87 GDSC2 5.9438 9.2364 3.5335 6.0934
MKN1 GDSC2 5.948 12.9487 1.7172 16.3685
SNU-5 GDSC2 6.1198 10.0565 3.2594 7.3522
MKN45 GDSC2 6.3395 7.7108 4.4436 0.6011
SK-GT-2 GDSC2 6.4276 8.5473 4.1433 1.8192
OCUM-1 GDSC2 6.6011 8.7669 4.139 1.6313
IM95 GDSC2 6.6575 8.8044 4.1514 1.5117
MKN28 GDSC2 6.7928 10.6826 3.3984 5.2385
KATO III GDSC2 6.8185 8.801 4.2288 1.0277
Hs 746.T GDSC2 6.9837 8.7661 4.3139 0.606
GCIY GDSC2 7.0324 10.8585 3.4603 4.5008
NUGC-4 GDSC2 7.1903 8.7782 4.3908 0.3015
RERF-GC-1B GDSC2 7.2176 12.2564 2.9328 7.0534
NUGC-3 GDSC2 7.2949 8.6763 4.4641 0.1398
HGC-27 GDSC2 7.5119 9.0731 4.4054 0.18
ECC10 GDSC2 7.8125 9.4007 4.3994 0.1291
SNU-1 GDSC2 7.8655 9.469 4.3947 0.126
SNG-M GDSC2 6.4059 8.431 4.1816 1.6602
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
FTC-133 GDSC2 5.7096 7.6303 4.1419 2.9467
B-CPAP GDSC2 5.9407 8.3486 3.9524 3.6157
ASH-3 GDSC2 6.1089 8.1881 4.1266 2.35
8305C GDSC2 6.3683 7.9692 4.3544 0.923
IHH-4 GDSC2 6.5591 7.9178 4.4572 0.4149
WRO GDSC2 6.6884 12.8565 2.301 11.557
K5 GDSC2 6.689 8.6039 4.2482 1.0641
BHT-101 GDSC2 6.781 11.4451 3.0365 7.2927
CAL-62 GDSC2 6.8894 8.702 4.2986 0.7166
8505C GDSC2 7.3147 9.3252 4.2403 0.6382
HTC-C3 GDSC2 7.4987 9.4599 4.2641 0.4781
TT2609-C02 GDSC2 7.6488 9.3328 4.365 0.212
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 GDSC2 5.5184 6.9165 4.3545 2.0681
HSC-3 GDSC2 5.7543 7.5518 4.2062 2.4933
SAS GDSC2 5.8831 9.4991 3.3647 7.2434
CAL-27 GDSC2 5.8967 8.579 3.8157 4.5038
UPCI-SCC-090 GDSC2 6.1207 10.2875 3.1487 8.0064
SCC-15 GDSC2 6.1699 8.7638 3.9017 3.4934
BICR 10 GDSC2 6.2797 12.558 2.1564 13.2695
NCI-H3118 GDSC2 6.5006 8.9436 4.0109 2.3864
BB49-HNC GDSC2 6.7349 9.1114 4.0618 1.8375
SCC-9 GDSC2 6.7413 8.8582 4.1699 1.3425
SCC-4 GDSC2 6.7506 8.952 4.1359 1.4817
Detroit 562 GDSC2 6.8289 8.5446 4.333 0.6416
BICR 22 GDSC2 6.8319 8.2072 4.4587 0.2835
Ca9-22 GDSC2 6.8969 9.0147 4.1795 1.1551
JHU-022 GDSC2 6.9932 12.2877 2.7766 8.3292
CAL-33 GDSC2 7.0241 9.0245 4.2324 0.8519
HSC-4 GDSC2 7.0341 8.2742 4.5092 0.1292
HO-1-N-1 GDSC2 7.0464 8.7639 4.3402 0.4922
DOK GDSC2 7.1189 11.1458 3.3811 4.7888
FaDu GDSC2 7.1536 15.5428 1.325 15.3866
BICR 78 GDSC2 7.1931 10.8992 3.5332 3.8707
OSC-20 GDSC2 7.3685 9.4801 4.2043 0.7172
LB771-HNC GDSC2 7.4891 9.5011 4.2453 0.5321
SKN-3 GDSC2 7.6251 9.6613 4.2402 0.4824
PCI-04B GDSC2 7.6455 9.6827 4.2404 0.4729
SAT [Human HNSCC] GDSC2 8.0582 10.4755 4.1134 0.6121
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
639V GDSC2 5.4785 7.8294 3.8903 4.9521
RT-112 GDSC2 5.6218 8.4015 3.7136 5.7102
SW780 GDSC2 5.6842 7.8168 4.0376 3.6114
J82 GDSC2 5.7932 8.1872 3.9335 4.0117
647V GDSC2 5.801 7.4809 4.2666 2.0746
HT-1197 GDSC2 6.1006 9.8785 3.3318 6.9633
KU-19-19 GDSC2 6.3196 7.8461 4.3813 0.8575
TCCSUP GDSC2 6.5317 10.0195 3.5443 4.8792
RT-4 GDSC2 6.5339 9.308 3.8687 3.0832
SW1710 GDSC2 6.6481 8.8517 4.1271 1.6332
CAL-29 GDSC2 6.8338 8.6401 4.2986 0.7557
BFTC-905 GDSC2 6.879 8.0717 4.5235 0.1421
5637 GDSC2 6.972 9.9212 3.8397 2.6178
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PA-1 GDSC2 5.2058 7.2503 3.974 5.0924
TC-YIK GDSC2 5.2866 7.0555 4.1303 3.9171
NEC8 GDSC2 5.305 7.697 3.8282 5.7554
SiHa GDSC2 5.5243 14.0469 0.8407 21.5422
HeLa GDSC2 5.7906 7.5435 4.232 2.2847
DoTc2 4510 GDSC2 5.809 8.0217 4.0218 3.4594
DSH1 GDSC2 5.8752 9.0391 3.5815 5.952
HT-3 GDSC2 6.2306 8.3921 4.1046 2.2844
ME-180 GDSC2 6.35 10.0012 3.4386 5.8251
LB831-BLC GDSC2 6.3929 8.6839 4.0658 2.2545
MS751 GDSC2 6.5708 8.3679 4.2882 1.0086
C-33 A GDSC2 6.6214 8.5285 4.2471 1.1314
CAL-39 GDSC2 6.7032 8.6558 4.2339 1.1093
Ca Ski GDSC2 6.7071 9.3245 3.9565 2.3828
BPH-1 GDSC2 6.7485 17.5044 0.0693 21.4563
SW756 GDSC2 6.8162 9.5406 3.9212 2.4163
PEO1 GDSC2 6.8406 10.2186 3.6369 3.8533
OVMIU GDSC2 6.8422 9.7615 3.8395 2.7914
HEC-1 GDSC2 6.9617 8.5863 4.3718 0.447
SiSo GDSC2 6.9632 9.1198 4.168 1.1431
OVCA420 GDSC2 6.9696 8.6748 4.3422 0.5276
HEY GDSC2 7.0076 8.9084 4.2699 0.7337
SKG-IIIa GDSC2 7.0571 8.5693 4.4149 0.2972
C-4-I GDSC2 7.2696 8.8004 4.4123 0.2315
PWR-1E GDSC2 7.3203 9.137 4.3118 0.4363
SKN GDSC2 7.3632 9.3214 4.2613 0.551
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from DTI-015 (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [13]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Thioguanine. Acute myeloid leukaemia [2A60] [14]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [15]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of DTI-015 and Roflumilast. Asthma [CA23] [16]
Ofloxacin DM0VQN3 Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [17]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [17]
Trovafloxacin DM6AN32 Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [17]
Sparfloxacin DMB4HCT Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [17]
Gemifloxacin DMHT34O Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [17]
Norfloxacin DMIZ6W2 Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [17]
ABT-492 DMJFD2I Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [17]
Levofloxacin DMS60RB Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [17]
Lomefloxacin DMVRH9C Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [17]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of DTI-015 and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [18]
Grepafloxacin DMGLX0T Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Grepafloxacin. Bronchitis [CA20] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Cannabidiol. Epileptic encephalopathy [8A62] [16]
Digoxin DMQCTIH Moderate Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Digoxin. Heart failure [BD10-BD1Z] [19]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Brentuximab vedotin. Hodgkin lymphoma [2B30] [20]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [21]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of DTI-015 and Mipomersen. Hyper-lipoproteinaemia [5C80] [22]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of DTI-015 and Teriflunomide. Hyper-lipoproteinaemia [5C80] [23]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of DTI-015 and BMS-201038. Hyper-lipoproteinaemia [5C80] [24]
Penbutolol DM4ES8F Minor Increased plasma concentration of DTI-015 and Penbutolol due to competitive binding of plasma proteins. Hypertension [BA00-BA04] [25]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Methotrexate. Leukaemia [2A60-2B33] [16]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of DTI-015 and Denosumab. Low bone mass disorder [FB83] [26]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [27]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Idelalisib. Mature B-cell leukaemia [2A82] [28]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Clofarabine. Mature B-cell lymphoma [2A85] [29]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of DTI-015 and Thalidomide. Multiple myeloma [2A83] [30]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of DTI-015 and Tecfidera. Multiple sclerosis [8A40] [31]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of DTI-015 and Siponimod. Multiple sclerosis [8A40] [13]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of DTI-015 and Fingolimod. Multiple sclerosis [8A40] [32]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of DTI-015 and Ocrelizumab. Multiple sclerosis [8A40] [33]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of DTI-015 and Ozanimod. Multiple sclerosis [8A40] [16]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of DTI-015 and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [34]
Gatifloxacin DMSL679 Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [17]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of DTI-015 and Canakinumab. Rheumatoid arthritis [FA20] [35]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of DTI-015 and Rilonacept. Rheumatoid arthritis [FA20] [35]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of DTI-015 and Golimumab. Rheumatoid arthritis [FA20] [36]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of DTI-015 and Leflunomide. Rheumatoid arthritis [FA20] [23]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of DTI-015 when combined with Anthrax vaccine. Sepsis [1G40-1G41] [37]
Cyclophosphamide DM4O2Z7 Moderate Decreased metabolism of DTI-015 caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [16]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [13]
Cisplatin DMRHGI9 Moderate Decreased metabolism of DTI-015 caused by Cisplatin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of DTI-015 and Naltrexone. Substance abuse [6C40] [39]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of DTI-015 and Azathioprine. Transplant rejection [NE84] [13]
Cinoxacin DM4EWNS Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [17]
Enoxacin DMYTE6L Minor Decreased absorption of DTI-015 due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [17]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of DTI-015 and Ganciclovir. Virus infection [1A24-1D9Z] [13]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of DTI-015 and Valganciclovir. Virus infection [1A24-1D9Z] [13]
⏷ Show the Full List of 51 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Carmustine 100mg/vial injectable 100mg/vial Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
2 Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Neuro Oncol. 2007 Jan;9(1):12-9.
3 Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
4 Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia. 2003 Jan-Feb;5(1):9-16.
5 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
6 BDDCS applied to over 900 drugs
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol. 2006 Nov;21(11):1199-207.
10 Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res. 1994 Nov;18(11):829-35.
11 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
12 Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006 Jan 10;24(2):274-87. doi: 10.1200/JCO.2005.02.9405. Epub 2005 Dec 19.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
15 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
18 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
19 Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R "Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations." Clin Pharmacol Ther 39 (1986): 25-8. [PMID: 3943266]
20 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
21 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
22 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
23 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
24 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
25 Aguirre C, Rodriguez-Sasiain JM, Calvo R "Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents." Cancer Chemother Pharmacol 34 (1994): 86-8. [PMID: 8174208]
26 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
27 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
28 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
29 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
30 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
31 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
32 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
33 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
34 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
35 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
36 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
37 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
38 Fassas A, Gojo I, Rapoport A, et al. "Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy." Bone Marrow Transplant 28 (2001): 399-403. [PMID: 11571514]
39 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.